Oramed Pharmaceuticals (ORMP) Non Operating Income (2022 - 2026)

Oramed Pharmaceuticals' Non Operating Income history runs 5 years deep, the most recent figure standing at $44.8 million for Q1 2026.

• Quarterly Non Operating Income rose 1853.28% year-over-year to $44.8 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $136.9 million (up 1477.98% YoY) and the FY2025 annual result came in at $89.5 million, up 4013.12% from the prior year.
• Non Operating Income was $44.8 million for Q1 2026 at Oramed Pharmaceuticals, up from $15.2 million in the prior quarter.
• Across five years, Non Operating Income topped out at $61.5 million in Q3 2025 and bottomed at -$15.4 million in Q3 2024.
• A 5-year average of $10.5 million and a median of $2.5 million in 2023 frame the typical range for Non Operating Income.
• Annual changes were most pronounced in 2024 — Non Operating Income plunged 3644.83% — and 2026, when it surged 1853.28%.
• Oramed Pharmaceuticals' Non Operating Income stood at $1.0 million in 2022, then soared by 1731.08% to $18.4 million in 2023, then plunged by 133.66% to -$6.2 million in 2024, then jumped by 345.25% to $15.2 million in 2025, then surged by 195.53% to $44.8 million in 2026.
• Business Quant data shows ORMP's Non Operating Income at $44.8 million in Q1 2026, $15.2 million in Q4 2025, and $61.5 million in Q3 2025.